Alzheimer's disease (AD) is one of the most prevailing neurodegenerative illnesses in the elderly. 
Introduction
Alzheimer's disease (AD) is a fatal and age-related neurodegenerative disorder characterized by memory loss and progressive cognitive impairment.
1,2 Currently, approved pharmacotherapies only provide short-term or mild relief from AD symptoms, but do not cure or prevent the process of AD.
3
Although the exact pathogenesis of AD is elusive, amyloid cascade hypothesis is the major etiologic basis for AD over the past few decades. It is believed that AD is caused by the accumulation of amyloid-b peptide (Ab), which initiates a sequence of pathogenic events, such as the formation of neurobrillary tangles (NFTs) and the onset of synaptic and neuronal dysfunction or death. 4 In AD pathogenesis, Ab species, mainly Ab40 and more toxic Ab42, 5 aberrantly aggregate from non-toxic monomers into toxic oligomers, brils, and eventually senile plaques. Plenty of evidence suggests that Ab aggregates, especially soluble oligomers, could impair synaptic and cognitive functions. 6 Thus, Ab oligomers and brils are regarded as the main therapeutic targets for AD. 7 Since Ab aggregation and its neurotoxicity could be aggravated by metal ions such as Zn 2+ and Cu 2+ in the AD brain, 8, 9 metal chelators that can regulate the distribution of metal ions are potential therapeutic agents for AD. 10, 11 Extensive studies have focused on the reduction of Ab or its aggregation by targeting Ab production or clearance, [12] [13] [14] [15] and some compounds have effectively prevented the de novo aggregation of Ab; however, they cannot eliminate the existing Ab oligomers and plaques in the brain. 16 Consequently, such strategies hardly improve the cognition of patients, and none of them have gone through clinical trials so far.
17,18
On the other hand, activated microglia in the central nervous system and increased inammatory mediators around Ab plaques in the brain of AD patients have been related to the pathogenesis of AD. Ab and NFTs can indirectly activate immune response or microglia and lead to the release of various pro-inammatory cytokines (PICs) and neurotoxic mediators. 19 Microglia have two phenotypes of activation: pro-inammatory M1 and immunosuppressive M2.
20 M1 is associated with releasing PICs, such as interleukin-1b (IL-1b), interleukin-6 (IL-6), tumour necrosis factor-a (TNF-a), superoxide, nitric oxide (NO), reactive oxygen species (ROS), and expressing inducible nitric oxide synthase (iNOS). These PICs and mediators not only attenuate the phagocytosis of Ab, 21 but also affect the tau pathological metamorphosis, increasing tau phosphorylation and accelerating tangle formation, 22 thereby inducing neurotoxicity. In addition, PICs and activated microglia could promote Ab production, exacerbating the formation of Ab brils and deposition. 23, 24 To make things worse, toxic Ab oligomers and brils could be recognized by some receptors expressed by microglia, 25, 26 triggering the microglial activation through nuclear factor-kappa B (NF-kB) or mitogen-activated protein kinases (MAPKs). 27 Aging and toxic conditions in the AD brain also favour the chronic activation of microglia and reduce their phagocytic capacity and prolong neuroinammation. 28 As a result, a vicious cycle between neuroinammation and Ab aggregation is formed, ultimately leading to the death of neurons and onset of AD. 29, 30 Thus, interfering with the vicious cycle may produce therapeutic effects on AD.
Anti-inammatory drugs were expected to reduce the risk of AD, but clinical trials for these drugs have failed. [31] [32] [33] [34] Considering the pathogenic effect of Ab aggregation and neuroinammation in AD, we suppose that defence against both Ab oligomers or plaques and PICs may produce a dual impact on the AD progression and protect the neurons in the brain. Herein we report a novel neuromodulator (BIBA, Fig. 1 ), which is a hybrid of a derivative of aspirin, a non-steroidal antiinammatory drug, and 2-(phenoxymethyl)-1H-benzoimidazole, an analogue of Ab-targeting thioavin T (ThT), for inhibiting the Ab aggregation and neuroinammation. As anticipated, BIBA showed remarkable inhibitory effects on selfand metal-induced Ab aggregations, and exhibited obvious antiinammatory activity by suppressing intracellular lipopolysaccharide (LPS)-or Ab-induced production of PICs in microglia. Moreover, it delayed the Ab-induced paralysis and increased the lifespan of transgenic Caenorhabditis elegans (C. elegans). A preliminary test suggests that BIBA could rescue the memory decits of the amyloid precursor protein/presenilin protein 1 (APP/PS1) mice through inhibiting Ab oligomerization and overactivation of microglia. To the best of our knowledge, BIBA is the rst anti-AD agent capable of regulating Ab aggregation and neuroinammation simultaneously.
Results and discussion
Design and synthesis of BIBA BIBA was designed by linking an Ab-targeting moiety with a derivative of aspirin. The 2-(phenoxymethyl)-1H-benzoimidazole group was selected due to its high lipophilicity and affinity for Ab aggregates;
35 the derivative of aspirin was chosen to suppress the generation of PICs by inhibiting cyclooxygenases (COXs). 36 In addition, a low dose of aspirin could decrease Ab plaques by upregulating the transcription factor EB, 37 and benet the inhibition of protein aggregation and corresponding toxicity through acetyl-donating activity. 38 The synthesis and characterization of BIBA are shown in Scheme S1 and Fig. S1 . † BIBA is stable over 24 h in buffer (pH 7.4), suggesting that it is suitable for biochemical experiments (Fig. S2 †) . The lipophilicity parameter (log P) of BIBA determined by the shakeask method is À0.04 AE 0.01, indicating that BIBA is more lipophilic than the aspirin derivative (log P ¼ À1.40 AE 0.07). According to Lipinski's "rule of ve", 39 BIBA could potentially cross the BBB (see Table S1 †). To verify the BBB-penetrating ability, we analyzed the brains of C57BL/6J mice aer intravenous injection of BIBA by HPLC. BIBA reached its maximum in the brain at around 10 min and attenuated gradually at 20 min aer injection (Fig. S3 †) . The results conrm that BIBA can cross the BBB. aggregations. The inhibitory effect of BIBA on Ab aggregation was examined by circular dichroism (CD) spectroscopy, which is extensively used to monitor the secondary structural conversion of proteins. As shown in Fig. 2A , the CD spectrum of Ab displays two negative peaks around 198 and 217 nm, which are characteristics of random coils and b-sheet conformation, respectively. When Ab was incubated with Zn 2+ or Cu 2+ , the negative peak at 198 nm disappeared and a new positive peak emerged around 194 nm, along with the increase of the negative peak around 217 nm. These changes indicate that the conformation of Ab is transformed from random coils to b-sheets, thus signifying the formation of Ab brils. The results are consistent with reported observations. 41, 42 Upon addition of BIBA, the negative band centred at 217 nm diminished, indicating that the level of Ab brils was decreased. The morphological changes of Ab in the absence and presence of metal ions and/or BIBA were directly visualized by transmission electron microscopy (TEM). As shown in Fig. 2B , some brils were observed in the solution of Ab, and large amounts of mature aggregates were seen in the presence of Zn 2+ and Cu
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2+
, indicating that soluble bsheet-rich brils and insoluble Ab aggregates are formed. Massive Ab aggregates were changed into short brils or sporadic granule-like species aer incubation with BIBA, showing that the Ab aggregations with or without metal ions were suppressed. The Western blot also showed that BIBA could inhibit the formation of insoluble Ab brils and increase the number of monomers (Fig. 2C ). The effect of BIBA on Ab42 aggregation was also analyzed by using CD spectra, TEM and Western blot ( Fig. S5 †) ; the results are consistent with those for Ab40. The CD spectra of Ab42 were somewhat different from those of Ab40 possibly because Ab42 aggregated into brils more quickly than Ab40, which was consistent with previous reports.
43-45
The interactions of BIBA with the Zn 2+ -or Cu 2+ -induced Ab40 aggregates were further investigated by ESI-MS. As shown in Fig. 2D and E, no peaks assignable to Ab40 species or BIBAAb40 adducts are observed aer the co-incubation of Ab40, metal ions and BIBA (see Tables S2 and S3 †), suggesting that no covalent interactions occurred between BIBA and Ab40. Noticeably, several peaks corresponding to BIBA-metal ions and BIBA-metal-Ab40 adducts were observed. All these results indicate that BIBA exhibits high potential to dissociate the Ab aggregates without or with metal ions, and the chelation is involved in the inhibition of metal-induced Ab aggregation.
Attenuation of Ab neurotoxicity
The transition of Ab from nontoxic monomers to toxic oligomers and plaques was believed to be a crucial reason for the neurotoxicity in AD. 46 In addition, Zn 2+ and Cu 2+ are able to stabilize the soluble Ab42 oligomers and hence aggravate the neuron death. 47, 48 The effect of BIBA on the Ab-induced neurotoxicity in the absence and presence of Zn 2+ or Cu 2+ was tested in the mouse neuroblastoma Neuro2a (N2a) cell line, which was usually used to evaluate the drug toxicity in the study of AD. 49 As shown in Fig. 3A , the viability of N2a cells treated with Ab42 alone or in the presence of metal ions was less than 70%, which is consistent with a literature report; 50 the viability increased remarkably when the cells were coincubated with Ab42 and BIBA in the presence and absence of metal ions. The results suggest that BIBA can effectively attenuate the cytotoxicity of Ab42 aggregates with or without metal ions. BIBA per se was almost non-toxic toward N2a cells even at 50 mM (Fig. S6 †) .
It is known that neuronal apoptosis induced by neurotoxic Ab aggregates plays a central role in triggering AD. The prevention of such apoptosis may represent an effective way for the treatment of AD. To explore the capability of BIBA to block the signalling pathway to Ab-induced neuronal cell death, the expression of apoptotic proteins in N2a cells stimulated by Ab42 in the presence of BIBA was measured by the Western blot. Among them, p53 is related to the induction of neuronal apoptosis in AD and believed to be one of the targets of nuclear Ab; 51 cleaved caspase-3 plays a critical role in the apoptotic signalling pathway; 52 cytochrome c (Cyto c) is released from the mitochondria into the cytoplasm to initiate apoptosis; Bax and Bad are pro-apoptotic proteins in the Bcl-2 protein family; and Bcl-2 is an anti-apoptotic protein that inhibits the activation of the apoptotic pathway. As shown in Fig. 3B , aer treatment with Ab42, the expression of p53, cleaved caspase-3, Cyto c, Bax, and Bad was dramatically increased, but that of Bcl-2 was decreased; however, aer addition of BIBA, the expression of pro-apoptotic proteins was down-regulated obviously, while that of Bcl-2 was upregulated. The results suggest that BIBA can prevent the apoptosis of neural cells induced by Ab.
Effect on paralysis and lifespan of transgenic C. elegans
Transgenic C. elegans strains expressing the human Ab gene in muscles or neurons are widely used as in vivo models of AD for examining the accumulation and toxicity of Ab and screening potential drugs, because the worms are simple in culturing and fast in generation, and have 302 neurons in hermaphrodites, a well-characterized nerve system, and a high level of homology with the human genome. [53] [54] [55] [56] [57] The expression of the Ab gene in muscles of C. elegans is associated with severe age-progressive paralysis, 58 which is an apparent symptom and also a measurable phenotype regarded as a consequence of Ab toxicity in these AD models. Hence, the effect of BIBA on the paralysis was investigated. In transgenic C. elegans strain CL4176, the aggregation of Ab1-42 in the muscle tissue is temperature-inducible, 59 which results in the time-dependent aggregation of Ab and paralytic phenotype. 60 This kind of worms produces low levels of Ab and moves as rollers when grown at 15 C (Fig. 4A top), and generates a large amount of Ab and becomes straight and loses the moving ability when the temperature was upshied to 25 C (Fig. 4A bottom) . Meanwhile, transgenic C.
elegans strain CL802 that does not express the Ab gene in muscle tissue 61 and aspirin-treated CL4176 were used as the controls. As expected, BIBA and aspirin decreased the percent of paralysis from 58.7% to 6.3% and 17.4%, respectively, at 34 h aer the temperature upshi (Fig. 4B) . In addition, 92.6% of the untreated worms became paralyzed aer 36 h, while only 27.2% of the BIBA-treated worms were paralyzed. By contrast, the mobility of the CL802 strain did not alter. These results indicate that BIBA can more effectively protect transgenic C. elegans against the Ab-induced paralysis than aspirin.
The effect of BIBA on the lifespan of CL4176 worms was further examined by analyzing the overall nematode survival. As shown in Fig. 4C and D, BIBA caused a signicant increase in the lifespan of CL4176 worms as compared with the control, suggesting that it can mitigate the Ab-related pathological threat to the worms. The same dose of aspirin was less effective for increasing the lifespan, which was consistent with the paralysis assay. We speculate that the advantages may arise from the synergistic effect of two functional moieties in BIBA. The administration of BIBA to wild-type (N2) worms at the L2 larval stage did not modify their survival (Fig. S7 †) , indicating that its toxicity is negligible.
The Ab deposits in transgenic CL4176 were rst examined by thioavin S (ThS, a dye for Ab plaques) staining, which could reect the inhibitory effect of BIBA on Ab aggregation through green uorescence. Fig. 4E shows that the Ab deposits were greatly reduced in worms fed with BIBA, while they did not respond obviously to aspirin. Furthermore, the Ab species from the CL4176 worms fed with or without BIBA were analyzed by the Western blot. As shown in Fig. 4F , the Ab-immunoreactive (6E10) bands of the tissues indicate that BIBA evidently reduced the amount of toxic Ab oligomeric species. The expression of COX-2, TNF-a, IL-6 and IL-1b in CL4176 worms was also measured by the Western blot aer the worms were fed with BIBA, aspirin or vehicle. As shown in Fig. 4G and H, the expression of PICs decreased markedly as compared with the control group. Apparently, the extension of lifespan and delay of paralysis in CL4176 by aspirin result from its anti-inammatory ability rather than inhibitory ability to Ab oligomerization, while the protective effect of BIBA against Ab-induced toxicity in the worms arises from its inhibition of Ab oligomerization and deposition as well as its anti-inammatory ability. Aspirin alone exhibits a much weaker effect than BIBA due to the lack of antiAb aggregation ability. 
Inhibition of PICs
The immune system could be overactivated indirectly and lead to the release of various neurotoxic mediators and PICs, which may contribute to neuronal damage or degeneration in the brain of AD patients. The pro-inammatory M1 phenotype of microglia is predominant at the site of neuroinammation and related to the release of PICs, which may cause tissue damage and cell death. During chronic activation of microglia, sustained exposure of neurons to PICs, such as IL-6, IL-1b, and TNF-a, can cause neuronal dysfunction and cell death. 62 To verify the anti-inammatory activity of BIBA, the expression of PICs and neurotoxic mediators in BV-2 microglia was investigated by the Western blot aer incubation with LPS or Ab42 and BIBA, with LPS-or Ab42-treated BV-2 cells as controls. As shown in Fig. 5A and B, the expression of PICs and mediators increased markedly when the cells were stimulated by LPS or Ab42 as compared with the control group; however, BIBA signicantly inhibited their expression under the same conditions. Cluster of differentiation 86 (CD86) is closely correlated with microglia overactivation and is regarded as a marker of the M1 phenotype of microglia. 63 To clarify the phenotype of BV-2 cells in the presence of BIBA, we detected the level of CD86 using immunohistochemistry. As shown in Fig. 5C , the expression of CD86 (red) was obviously increased in the Ab-exposed microglia, and decreased aer treatment with BIBA, suggesting that BIBA can protect BV-2 cells from overactivation induced by Ab42. This deactivation ability towards microglia is more obvious than that of adiponectin, an adipokine derived from adipose tissue.
64
Reduction of Ab oligomers and overactivation of microglia in vivo APP/PS1 double-TG model mice produce elevated levels of human Ab by expressing mutant human APP and PS1, forming amyloid plaques as early as 4 months old and losing cognition when 6-8 months old. 65 To verify the inhibitory effect of BIBA on the formation of Ab oligomers and plaques in vivo, the brains of the BIBA-treated APP/PS1 mice were examined by immunohistochemical analysis and the Western blot. As shown in Fig. 6 , green uorescence spots of Ab plaques are observed in the brain of untreated and aspirin-treated 9-month old mice aer staining with ThS, which could visualize the dense-core Ab plaques, 66 while the formation of plaques was dramatically inhibited in C for 12 h, and (C) immunofluorescence images showing the expression of CD86 in Ab-exposed BV2 microglia in the presence or absence of BIBA. The results are presented as mean AE SEM (n ¼ 2); ****P < 0.0001, ***P < 0.001, **P < 0.01 and the BIBA-treated APP/PS1 mice. The formation of Ab oligomers was also examined by the Western blot. BIBA greatly decreased the amount of oligomeric species in soluble fractions; however, the effect of aspirin seems to be weaker than the reported observations possibly due to the lower dosage (Fig. S8 †) . 34 Ab monomers did not appear because in APP/PS1 mice Ab exists mainly in the form of neurotoxic oligomers. These results are consistent with those observed for C. elegans, thus conrming that BIBA can effectively reduce the Ab plaques and oligomers formed in the brain of AD mice.
Abnormal accumulation of Ab induces overactivation of microglia in the brain, which is closely associated with neuron injury in AD.
67 Calcium-binding protein Iba-1 is specically expressed in brain microglia and up-regulated in activated microglia.
68 Therefore, we detected the Iba-1-positive cells and the expression of Iba-1 in the brain of APP/PS1 mice by immunouorescence staining. As shown in Fig. 6 and S9, † strong activation of microglia (red spots) was found around the Ab plaques (green spots) in the brain of APP/PS1 mice; by contrast, BIBA markedly reduced the expression of Iba-1. Aspirin did not show signicant effects on the activation of microglia. These results show that the aberrant elevation of microglia activation in the APP/PS1 mice was alleviated and the surrounding Ab species was reduced aer the administration of BIBA.
In view of the above properties, we assessed the protective effect of BIBA on the spatial judgement and hippocampal memory of APP/PS1 mice (6-month-old, male) by Morris water maze (MWM) tests aer drug administration for 3 months. 69 On the 4th day during the acquisition phase, the BIBA-treated APP/ PS1 mice seem to perform better than the aspirin-treated and the control group, as reected by a reduction in escape latency time (Fig. S10B †) , with more annulus crossing and longer time spending in the target quadrant in the probe trial (Fig. S10C and  D †) . No obvious toxicity was observed on BIBA at a dose of 10 mg kg À1 based on the mortality, changes in body weight and hair loss (Fig. S11 †) . These preliminary results suggest that BIBA could ameliorate the Ab-related learning and memory decits in the APP/PS1 mice.
Mode of interaction between BIBA and Ab
Given that BIBA can inhibit the self-or metal-induced Ab aggregation and prevent Ab-induced cell death, we hypothesized that BIBA may interact with Ab monomers or oligomers noncovalently and interfere with the formation of brils. In order to further understand the possible molecular mechanism for the inhibiton of Ab aggregation by BIBA, we adopted the crystallographic data of Ab40 and optimized the geometry of BIBA to perform the blind docking calculations using Autodock soware. 42, 70 As shown in Fig. 7A , there are seven amino acid residues in Ab40, which are Glu-22, Phe-19, Val-18, Lys-16, Gln-15, His-6, and Arg-5, taking part in the interaction with BIBA. Among them, Val-18 and Phe-19 are hydrophobic, and the rest are hydrophilic. Two hydrogen bonds involving Gln-15 (2.6871Å) and Lys-16 (2.4672Å) are associated with BIBA, implying that hydrogen bonding as well as hydrophobic and van der Waals forces contributed to the interaction. In Ab40 brils, BIBA is located in the central hydrophobic residues and remains in contact with Ile-31 and -32 through hydrogen bondings (Fig. 7C) . The interaction energies between BIBA and related amino acids of Ab40 monomers or brils are listed in Table S4 . † These results illustrate that BIBA may interfere in the Ab self-aggregation through weak interactions with the amino acid residues in Ab40. Fig. 7B and D depict the lowest energy conformation of BIBA with monomeric and brillar Ab40, respectively. The weak interaction between BIBA and Ab40 was further studied by 1 H NMR. The proton signals assignable to the imidazole of His residues only slightly shied in the presence of BIBA (Fig. S12 †) , which suggests that BIBA may affect the chemical environment of protons in Ab40 through H-bonding interactions.
71
Conclusions
Alzheimer's disease is characterized by several hallmarks, including Ab plaques, NFTs, overactivation of microglia, neuronal loss and cognitive impairment. 72 Currently, many single-targeted drug candidates are designed to solubilize Ab aggregates or dissociate NFTs, and some of them have entered different stages of pre-clinical or clinical development. However, most of them failed nally in clinical trials, suggesting that single-target drugs only achieve limited effects on the AD progression. 73, 74 AD is usually diagnosed at late stages when substantial Ab aggregates and PICs are produced, and irreversible neuron death and cognitive impairments have occurred. Hence, drugs with Ab aggregates or inammation as the single target cannot break the vicious cycle between Ab aggregation and neuroinammation. By contrast, dual-target BIBA signicantly decreased the level of Ab brils and inhibited the self-or metal-induced Ab aggregation; meanwhile, it suppressed the intracellular expression of pro-inammatory mediators and cytokines, thereby protecting microglia from overactivation induced by Ab42. In addition, BIBA could reduce the expression of apoptosis-related proteins and prevent the apoptosis of neural cells induced by Ab aggregates. The synergistic effect between the inhibition of Ab aggregation and suppression of neuroinammation exerted by BIBA is depicted in Fig. 8 .
In conclusion, a difunctional neuromodulator (BIBA) was designed in this study. BIBA can (1) inhibit self-and metalinduced Ab aggregations, (2) diminish neuroinammation in microglia, (3) prolong the lifespan and attenuate Ab-induced paralysis in Ab-transgenic C. elegans, and (4) reduce Ab plaques, oligomers and neuroinammation in the brain of AD model mice. Mechanism studies suggest that BIBA holds back the metal-induced Ab aggregation by chelating with metal ions, interferes with the Ab self-aggregation by interacting with amino acid residues, and inhibits the neuroinammation by suppressing PICs in microglia. Therefore, BIBA is a multi-target anti-AD agent that may alleviate the progress of AD through a synergistic mechanism. The design of BIBA represents a new conception for the treatment of AD and opens a promising avenue for the development of anti-AD agents.
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